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Abstract
Influenza virus inflicts a heavy death toll annually and resistance to existing antiviral drugs has generated interest in the development
of agents with novel mechanisms of action. Favipiravir is an antiviral drug that acts by increasing the genome-wide mutation rate of
influenza A virus (IAV). Potential synergistic benefits of combining oseltamivir and favipiravir have been demonstrated in animal
models of influenza, but the population-level effects of combining the drugs are unknown. In order to elucidate the underlying
evolutionary processes at play, we performed genome-wide sequencing of IAV experimental populations subjected to serial pas-
saging in vitro under a combined protocol of oseltamivir and favipiravir. We describe the interplay between mutation, selection, and
genetic drift that ultimately culminates in population extinction. In particular, selective sweeps around oseltamivir resistance muta-
tions reducegenome-widevariationwhiledeleteriousmutationshitchhike tofixationgiven the increasedmutational loadgenerated
by favipiravir. This latter effect reduces viral fitness and accelerates extinction compared with IAV populations treated with favipiravir
alone, but risks spreading both established and newly emerging mutations, including possible drug resistance mutations, if trans-
mission occurs before the viral populations are eradicated.
Key words: influenza, population genetics, genetic hitchhiking, mutational meltdown.
Introduction
Influenza A virus (IAV) inflicts a heavy disease burden world-
wide, thus developing effective drugs remains a public health
priority. The most frequently used drug, oseltamivir, was
designed as a competitive inhibitor of the viral surface neur-
aminidase (NA) glycoprotein responsible for binding host cell
sialic acid to enable the release of virus progeny (Moscona
2005). Oseltamivir binding requires altering a hydrophobic
pocket in the NA region and can be destabilized by mutations
near the active site (Varghese et al. 1998; Collins et al. 2008).
Early studies in vitro and in vivo identified high fitness costs
associated with such mutations, which lent support to the
view that the development of resistance was unlikely in clinical
settings (Ives et al. 2002). The most common resistance mu-
tation in H1N1 strains, NA H275Y, was initially observed in-
frequently during clinical testing (Gubareva et al. 2001) but
spread rapidly worldwide during the 2007/2008 influenza
season (Moscona 2009) and continues to be a clinical concern
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(Ghedin et al. 2012; Meijer et al. 2014; Takashita et al. 2015).
H275Y confers resistance to oseltamivir but lowers viral fitness
by reducing the amount of NA that reaches the cell surface
(Bloom et al. 2010). The higher than expected fitness of
mutants carrying H275Y is likely due to the presence of com-
pensatory mutations that increase cell surface expression and
enzymatic activity of NA (Bloom et al. 2010; Bouvier et al.
2012; Ginting et al. 2012; Butler et al. 2014).
Oseltamivir resistance has increased interest in developing
drugs with an alternative mechanism of action and a lower
likelihood of resistance. Favipiravir is a mutagenic drug that
inhibits the viral RNA-dependent RNA polymerase (RdRp) and
dramatically increases the IAV mutation rate, ideally driving
the virus towards extinction (Baranovich et al. 2013; Furuta
et al. 2013). Over the past few decades, several studies have
shown the impact of mutagenic drugs on RNA virus extinction
(e.g., foot-and-mouth disease virus [Sierra et al. 2000;
Pariente et al. 2001], HIV-1 [Loeb et al. 1999; Loeb and
Mullins 2000], and lymphocytic choriomeningitis virus
[Grande-Pe´rez et al. 2002]). Favipiravir is effective against a
range of RNA viruses including influenza and is currently in
phase III clinical trials. It is safe for use in humans in part be-
cause human proteins do not contain RdRp domains, and it
has a distinct mode of action from both oseltamivir and M2
inhibitor drugs. Most importantly, no resistance mutations
have been functionally validated to date, in part because
the development of resistance may involve multiple muta-
tional steps, or perhaps because viral extinction occurs too
rapidly for resistance to evolve.
Under serial passage in cell culture with an escalating con-
centration of favipiravir, IAV populations steadily accumulate
an increasing mutation load (Bank et al. 2016), leading to an
eventual sharp population collapse and extinction. Results fit
predictions of the mutational meltdown model (Lynch et al.
1993). Specifically, Muller’s ratchet (the stochastic loss of the
fittest class of haplotypes and resulting reduction in fitness)
(Muller 1964; Felsenstein 1974) and Hill–Robertson interfer-
ence (the reduction in the efficacy of selection owing to link-
age between selected sites) (Hill and Robertson 1966) have
been argued to be the key drivers of this process. Notably, in
cell culture experiments with IAV, extinction depends on a
high concentration of favipiravir; when the drug concentra-
tion was held constant at low levels, or withdrawn, a reduc-
tion in the negative growth rate (relative to the no-drug
control) was observed in some populations (Bank et al. 2016).
Using drugs in combination is an established clinical strat-
egy aimed at preventing or delaying resistance by rapidly de-
pleting pathogen populations before resistance can emerge
(Mitchison 2012). Synergistic benefits have been observed
using favipiravir and oseltamivir in combination against pan-
demic influenza A/California/04/2009 (H1N1 pdm) as well as
against oseltamivir resistant (H275Y NA mutation) influenza in
mice in vivo (Smee et al. 2013). However, given the two very
different mechanisms of action, the effects of combining
these drugs on the emergence of drug resistance are un-
known. To assess the potential advantage of a combined pro-
tocol, we treated IAV populations with escalating
concentrations of oseltamivir and favipiravir (“combined
drug” populations) over ten passages in cell culture, and com-
pared these with three paired control replicate IAV popula-
tions treated with oseltamivir only, as well as with our
previously generated favipiravir only and no-drug control pop-
ulations. This experimental set-up offered an excellent plat-
form to dissect the complex dynamics contributing to
mutational meltdown, and in particular the roles of genetic
hitchhiking, Muller’s ratchet, and Hill–Robertson interference.
In addition, the generation of replicates allows us to assess the
reproducibility of the observed evolutionary phenomena.
Fundamentally, our results demonstrated that viral growth
in oseltamivir-treated replicates remains high and stable
throughout all passages due to the emergence of resistance
mutations, whereas the combined drug populations become
extinct or near extinct over ten passages (i.e., 130 genera-
tions). Important differences were observed in the underlying
dynamics compared with the favipiravir-alone population.
Intriguingly, extinction proceeded more quickly in the com-
bined drug compared with the favipiravir-alone population
despite a lower number of segregating mutations. Results
suggest that this is due to the hitchhiking of deleterious muta-
tions with strongly selected oseltamivir resistance mutations, a
process that reduces viral fitness and accelerates extinction.
These selective sweeps depressed genetic variation, providing
an explanation for the lower number of segregating muta-
tions. Additionally, evidence of a small and rapidly declining
effective population size supports a role for Muller’s ratchet.
Finally, evidence of Hill–Robertson interference specific to the
combined drug and favipiravir populations emerged.
We did not find evidence here that the oseltamivir resis-
tance mutation NA H275Y arose earlier in combined oselta-
mivirþ favipiravir drug replicates than in oseltamivir replicates.
Rather, our results suggest that the mutational effect of favi-
piravir combined with oseltamivir more broadly explores se-
quence space, clustering beneficial mutations on the same
haplotype and generating alternative NA mutations, although
at the cost of a high linked mutation load. Thus, the combined
drug protocol potentially drives an earlier extinction point for
viral populations compared with the favipiravir protocol alone,
but at the risk of first introducing novel mutations that may be
beneficial for resistance into the population.
Materials and Methods
Experimental Details
We compared the evolution of influenza A/Brisbane/59/2007
(H1N1) in Madin–Darby canine kidney cells under treatment
with oseltamivir alone or under treatment with a combination
of oseltamivir carboxylate (F. Hoffmann-La Roche Ltd, Basel,
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Switzerland) and favipiravir (FUJIFILM Pharmaceutical USA,
Inc.) over a total of 10 passages. In the first three passages,
IAV was adapted from chicken egg and serially amplified in
the MDCK cells with no treatment, as part of an earlier ex-
periment (Foll et al. 2014). Stock viral populations from an
earlier experiment were used to seed passage 4 to ensure that
replicates are identical before administration of the drug treat-
ment. In passages 4–10, three replicates of IAV were exposed
to increasing concentrations of a combination of oseltamivir
and favipiravir (fig. 1). While such increasing concentrations
do not directly relate to patient-treatment strategies, this ap-
proach was chosen simply to study the adaptive potential of
the experimental populations. The replicates were paired with
three populations exposed to increasing doses of oseltamivir
only as a control. This ensured that the oseltamivir only rep-
licates are subject to the same experimental conditions as the
populations exposed to the combination treatment. A multi-
plicity of infection (MOI) of 0.01 was used for each passage in
all replicates, except at passage 10 (MOI¼ 0.005) in replicate
1. As in Foll et al. (2014), 13 viral generations are assumed to
occur during each passage. Details of drug treatment, MOI,
and output plaque forming units (PFU) for each replicate are
shown in supplementary table 1, Supplementary Material on-
line. These results were compared with results obtained from
a previous experiment, where two populations of IAV were
exposed to favipiravir alone and to a no drug control over
passages 4–15 (Bank et al. 2016). The favipiravir-only popu-
lation was treated with 2mM of the drug from passage 4, and
the concentration was doubled at every passage, which rep-
resents twice the level of drug administered in the combined
drug replicates (1mM favipiravir in passage 4 and doubling of
the dose thereafter). At the end of each passage, samples
from each replicate were sequenced using high coverage,
whole genome high throughput population sequencing as
previously described (Bank et al. 2016).
WFABC Analysis
In oseltamivir-treated replicates, the software developed by
Foll et al. (2014) was used to estimate global effective popu-
lation size Ne and site-specific selection coefficients s from
time sampled data using an approximate Bayesian computa-
tion approach. Because the frequency of the third most fre-
quent mutation is very low in this data set, all sites are treated
as bi-allelic. Sites with coverage >100 were randomly (hyper-
geometrically) down-sampled to a sample size of 100. Only
trajectories with a down-sampled frequency>2.5% were
kept for the analysis, to ensure that these are above the esti-
mated sequencing error of 1%. Following Foll et al. (2014),
mutations with a Bayesian posterior distribution for s exclud-
ing zero of<0.5% (P(s< 0jx)<0.5%) were identified as being
putatively positively selected.
Population Size Estimates
WFABC implements a block bootstrap approach to obtain a
distribution P(NejT(X)) for the effective population size Ne,
where T(X) is a single statistic based on the temporal method
of (Jorde and Ryman 2007). This method uses Fs’, which is a
measure of the variance in allele frequencies between two
time points adjusted for sampling bias to calculate Ne
Fs ¼
P ðx  yÞ2
P
zð1  zÞ
Fs0 ¼ 1
txy
Fs 1  12~n
  2~n
1 þ Fs4
 
1  1~n
 
where Fs is the estimator for allele frequency variance before
adjusting for sampling bias, x and y are the allele frequencies
at the two time points, txy is the number of generations be-
tween the two time points, z is the average frequency where
z¼ (xþ y)/2, and ~n is the harmonic mean of the sample sizes
nx and ny at each time point. Ne is calculated as 1/Fs’.
A second method for calculating effective population size
uses the harmonic mean of census sizes (Ewens 1967).
Population Dynamics
Absolute growth rates for all replicates were obtained
from the starting and final population sizes at each passage.
Fig. 1.—Experimental set-up. In each of three replicates, influenza A
virus was serially passaged in MDCK cells and exposed to increasing con-
centrations of either oseltamivir only, or of oseltamivir and favipiravir com-
bined, from passage 4 onwards. The multiplicity of infection (MOI) used to
seed each passage is shown on the right hand side. ED50 represents a 50%
effective dose for drug-naı¨ve virus. The MOIs are valid for all replicates
except combined drug and oseltamivir replicate 1 passage 10, where an
MOI of 0.005 was applied.
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The underlying assumption is that each viral plaque is the
result of a single infective particle, based on the low MOI
used for each passage. Following Foll et al. (2014) and Bank
et al. (2016), we assume 13 generations of viral populations
per passage and calculate the Malthusian growth rate r per
passage as
N tð Þ ¼ N1ð exprtÞ
where t is the number of generations, N(t) is the population
size at time t, andN1 is the initial population size at the start of
each passage.
Hierarchical Clustering Analysis
The hierarchical clustering analysis is based on the squared
Euclidian distance between allele frequency trajectories of
the candidate mutations using Ward’s (1963) minimum var-
iance criterion, starting from the time point where the fre-
quency was higher than the estimated sequencing error of
1%. Additionally, pairwise correlations between allele trajec-
tories were calculated and are reported in supplementary ta-
ble 4, Supplementary Material online.
Results and Discussion
Rapid Extinction of Combined Drug Replicates
We first confirmed that the combination of favipiravir and
oseltamivir leads to the extinction of virus populations under
serial passaging (see experimental design in fig. 1), consistent
with the effect of favipiravir shown in our previous study
(Bank et al. 2016). All combined drug replicates reached ex-
tinction or near extinction by passage 10 (i.e., after 130
generations). The output number of plaque-forming units
per ml (PFU/ml) tracks census viral population size at the
end of each passage. The output PFU/ml declined to
3.0102 for replicate 1, 8.0103 for replicate 2, and
2.4104 for replicate 3 (supplementary table 1,
Supplementary Material online). In contrast, the output PFU/
ml for oseltamivir-only replicates remained high and stable
throughout all passages (6.0105 PFU/ml for replicate 1,
5.0106 PFU/ml for replicate 2 and 7.0106 PFU/ml for rep-
licate 3), indicating that the virus developed resistance to this
drug (see section on resistance to oseltamivir for further
details).
We calculated relative viral growth per passage (a measure
of the fitness of the viral population) as output/input PFU/ml
and show its progression in figure 2A. The relative growth for
combined drug replicates declined more rapidly than for the
population treated with favipiravir alone, despite the lower
concentration of favipiravir. The relative growth for combined
replicate 1 showed a sharp recovery at passage 7 followed by
a rapid decline, whereas the relative growth for the other two
replicates declined steadily. Relative growth for the oseltamivir
replicates remained stable, although below the level exhibited
by the control population.
We estimated the total number of sites segregating above
a 1% derived allele frequency (DAF) (the estimated sequenc-
ing error) in the populations at each passage (fig. 2B), to ex-
plore whether a higher segregating mutation load was
responsible for the rapid decline of combined drug replicates
(see Materials and Methods). Intriguingly, the number of seg-
regating mutations was lower for the combined drug repli-
cates than for the favipiravir-only population. Further, peaks in
the number of segregating mutations at passage 6 for the
combined drug replicate 1 and passage 8 for the combined
drug replicate 2, followed by a rapid reduction, were likely
hallmarks of genetic hitchhiking (see below). In contrast,
oseltamivir-only replicates exhibited constantly low mutation
loads and stable viral population sizes, confirming that these
populations remained in mutation–selection–drift balance af-
ter achieving resistance.
A
B
Fig. 2.—Relative growth and total number of segregating sites in IAV
treated with zero, one (“osel” for oseltamivir), or two antiviral agents
(“comb” for combined favipiravir and oseltamivir). (A) Relative growth,
a measure of viral fitness, is calculated as log10(output/input PFU) for each
passage. A more rapid decline in relative growth was observed in the
combined drug replicates (red), than in the favipiravir-only population (yel-
low). Relative growth for the oseltamivir-only replicates (blue) remains
relatively stable, although below the level exhibited by the control popu-
lation (gray). (B) The number of segregating mutations represents all sites
segregating at>1% DAF at each passage. Despite the more rapid decline
in relative growth, the number of segregating sites for the combined drug
replicates (red) is lower than for the favipiravir population (orange), indi-
cating a lower segregating mutation load. The number of segregating sites
observed in the oseltamivir replicates is low, likely owing to selective
sweeps around the oseltamivir resistance mutations, as well as to the
absence of favipiravir’s mutagenic effect.
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Combined drug replicate 1 provided the strongest evi-
dence of transition into a phase of rapid population collapse
(negative relative growth) and escalating mutation accumula-
tion, similar to the dynamics observed in passage 14 and 15 of
the favipiravir population. The total number of segregating
mutations increased nearly 9-fold, specifically from 202 in
passage 9 to 1,800 in passage 10. For replicates 2 and 3, a
slowing of relative growth and an increase in the number of
segregating sites above the levels exhibited by oseltamivir-only
control replicates was observed, but the end dynamics indi-
cated that these replicates had not yet transitioned into pop-
ulation collapse.
Evidence for the Role of Muller’s Ratchet
An explanation for the rapid decline in relative viral growth in
combined drug replicates as opposed to individual drug ap-
plication is the accelerated action of Muller’s ratchet, and
generally less efficient selection, in smaller populations.
Under Muller’s ratchet, the mean number of deleterious
mutations per individual accumulates at a constant rate
(Muller 1964; Felsenstein 1974), assuming a static mutation
rate and constant population size. The rate of this process—
the speed of the ratchet—increases exponentially with muta-
tion rate and decreases with population size and with the
selection strength of deleterious mutations (Haigh 1978;
Gordo and Charlesworth 2000a, 2000b). In combined drug
and favipiravir-only treated populations subject to an influx of
mainly deleterious and neutral mutations, we would expect
an acceleration in the rate of Muller’s ratchet, particularly in
the case of declining population size. These evolutionary pro-
cesses are determined by effective population size Ne rather
than census size (Wright 1931; Charlesworth 2009). The serial
passaging of virus populations created a series of bottlenecks
followed by exponential growth (or contraction) over 13 viral
generations at each passage, which depressed effective pop-
ulation size. Strong purifying selection in IAV populations (evi-
denced by low average expected heterozygosity and a left
skew in the site frequency spectrum (SFS), supplementary
figs. 1 and 2, Supplementary Material online) also acted to
reduce effective population sizes (Charlesworth et al. 1993;
Gordo and Charlesworth 2001). Thus, we explored whether
differences in effective population size exist between the
favipiravir-only and combined drug replicates, and used this
as a means to indirectly assess the contribution of Muller’s
ratchet, and to quantify the rate of mutation accumulation.
Theoretical work and simulations have shown that the fix-
ation of neutral and weakly deleterious mutations is a robust
indicator of the loss of the least loaded classes and therefore
of the speed of Muller’s Ratchet, assuming a haploid asexual
population under an influx of deleterious mutations with the
same selection coefficient (Charlesworth and Charlesworth
1997; Bergstrom and Pritchard 1998; Gordo and
Charlesworth 2001). However, because of strong purifying
selection (supplementary figs. 1 and 2, Supplementary
Material online), here we observed a relatively small number
of mutations segregating above a DAF of 40% and fixing in
the population (supplementary table 2, Supplementary
Material online), most of which can be attributed to genetic
hitchhiking (discussed below). Therefore, the rate of fixation
of deleterious mutations in this case is rather conflated be-
tween the rate of genetic hitchhiking and the speed of the
ratchet.
Global estimates of effective population size were calcu-
lated to enable a comparison between the favipiravir-only
treated population and the combined drug replicates (fig.
3). These were obtained 1) by calculating the effective popu-
lation size at each passage based on the harmonic mean of
the estimated population size for each generation (assuming
exponential growth) and 2) by calculating the harmonic mean
of the estimates per passage (Ewens 1967). However, this
method ignores differences in virion budding, which create
skewed offspring distributions (Irwin et al. 2016) consistent
with evidence that only a few virions seed subsequent gen-
erations (Grenfell et al. 2004). Calculations of effective pop-
ulation size are therefore likely to be overestimated. We found
that the estimated effective population size for the combined
drug replicate 1 (Ne¼2,750) was similar to that for the
favipiravir-only population over 13 passages (Ne¼3,200), con-
sistent with the observation of a collapse in both of these
populations. Estimated effective population sizes in combined
replicates 2 and 3 were also low and below estimates for
Fig. 3.—Global effective population sizes. Effective population sizes
at each passage are calculated as the harmonic mean of estimated pop-
ulation sizes at each generation (assuming exponential growth over 13
generations for each passage). Estimates are calculated over eight pas-
sages (passages 3–10) for the combined drug and oseltamivir treated
replicates and over 13 passages (passages 3–15) for the favipiravir and
no drug populations (“favi 15p” and “no drug 15p”). For comparison
purposes, effective population sizes are also calculated over eight passages
(passages 3–10) for the favipiravir and no drug populations (“favi 10p”
and “no drug 10p”).
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oseltamivir-only and no-drug populations. A second estimate
of effective population size is obtained from Wright–Fisher
approximate Bayesian computation, or WFABC (supplemen-
tary fig. 3, Supplementary Material online), which leverages
the variance in allele frequencies between time points (Jorde
and Ryman 2007). This method is anticipated to be down-
wardly biased owing to the increasing mutation rate through
time in this experiment. Using this method, we also found
that estimates of effective population size for combined
drug replicates (Ne ¼ 239.16 for replicate 1, Ne ¼ 216.19
for replicate 2 and Ne ¼ 161.64 for replicate 3) were similar
to the estimate for the favipiravir-only population (Ne
¼ 209.15) and were lower than estimates for oseltamivir-
only replicates. Thus, the small effective population size pro-
cesses described were likely equally at play in precipitating
extinction in combined drug replicates as well as in the
favipiravir-alone populations.
Mutations Putatively Evolving under Positive Selection
To identify positively selected mutations, the posterior distri-
butions for estimates of s were utilized (i.e., with a posterior
density interval for the selection coefficient s excluding zero of
<0.5%, P(s< 0jx)< 0.005). WFABC differentiates trajectories
of mutations under selection from those due to genetic drift
under the assumption that all sites are unlinked and indepen-
dently selected, and that the mutation rate is static. Because
many of the trajectories in the oseltamivir-only, combined
drug, and favipiravir-only replicates exhibited nonstandard
trajectories (i.e., trajectories that have an exceedingly small
probability under any single selection coefficient), and be-
cause the assumptions of a constant mutation rate and of
unlinked sites did not always hold, we also tracked trajectories
that exceed a DAF of 40% at any time point.
We identified 11 mutations that potentially evolved under
positive selection in oseltamivir-only replicates (see fig. 4A–C),
including the known resistance mutation NA H275Y (based
on N1 numbering). Four of these mutations were synony-
mous and seven were nonsynonymous. The seven nonsynon-
ymous contending mutations were also the only ones that
arose in more than one replicate (outside of the NA region)
in either the combined drug replicates or in the favipiravir-only
treated population. Neutrality was rejected for all of these
mutations in at least one oseltamivir-only replicate (except
for NP D101N, which only exhibited a “standard” trajectory
in the favipiravir-only population) and WFABC was used to
estimate selection coefficients and Bayesian P values (table 1).
The varied trajectories and limited clustering of these muta-
tions in oseltamivir-only replicates supports the assumption
that these are unlinked, independently selected sites, al-
though epistatic interactions cannot be excluded.
In contrast, three of the four synonymous mutations to
reach a DAF >40% arose in one oseltamivir-only replicate;
two cluster with the strongly selected H275Y (HA L73L in
oseltamivir 1 and NA P326P in oseltamivir 2) suggesting prob-
able genetic hitchhiking of neutral variants. The third (PA
D67D) had a nonstandard trajectory and its functional sig-
nificance is unknown. The fourth synonymous mutation,
PA G58G, arose in all oseltamivir and combined drug rep-
licates, as well as in the favipiravir population. It fixed in
oseltamivir replicate 1 (along with MP1 E23Q) but exhibits
nonstandard trajectories in other oseltamivir and com-
bined drug replicates, as well as in favipiravir-only and
no-drug replicates, where it clustered with MP1 E23Q,
suggesting both a cell adaptation function and a possible
epistatic interaction with MP1 E23Q.
Figure 4 tracks these contending mutations potentially
evolving under positive selection in combined drug replicates
(fig. 4D–F) and in favipiravir-only and no-drug treated popu-
lations (fig. 4G and H). In addition to H275Y, two other non-
synonymous mutations (A454V and E128G) in the NA region
that is critical for oseltamivir resistance arose in the combined
drug replicates only; one of these mutations, NA A454V arose
in both combined drug replicates 2 and 3. In addition to the
11 mutations described earlier, this gives a new total of 13
contending beneficial candidates that are tracked in the com-
bined drug (fig. 4D–F) and in the favipiravir-only (fig. 4G) and
no-drug (fig. 4H) populations (table 1). Outside of the NA
region, the HA region contains the mutations with the highest
selection coefficient estimates: D112N and E78G. This is
consistent with studies showing that changes in the HA
region may counter the deleterious growth effects of
H275Y (Bloom et al. 2010; Ginting et al. 2012). The HA
D112N mutation was previously identified by Foll et al.
(2014) and has been described in other influenza strains
and HA serotypes (Daniels et al. 1985; Reed et al. 2009): it
acts by inducing a pH change at the point of endosome
and viral fusion, thereby improving IAV infectivity
(Thoennes et al. 2008). Here it was significant in oselta-
mivir replicate 2 (s¼ 0.126, table 1) and in the no-drug
comparison population, suggesting an additional role in
cell adaption. A newly identified HA mutation, E78G, was
present in all oseltamivir and combined drug replicates
where H275Y was present (five out of six populations),
but not in combined drug replicate 2 where H275Y was
absent, indicating a possible epistatic interaction. E78G
was significant in oseltamivir replicate 1 and 3 (s¼ 0.114
and s¼ 0.117 respectively, table 1) and fixed in combined
replicate 3, whereas in oseltamivir 2 and combined repli-
cate 1 its trajectory suggests clonal interference (see sec-
tion on Hill–Robertson Interference).
Mutations in the M1 region have been suggested to have
compensatory benefits upon interacting with H275Y by im-
proving the process of virion budding and helping to over-
come the fitness cost of the H275Y mutation, reflected in the
lower amount of NA to reach the cell surface (Jin et al. 1997;
Noton et al. 2007; Rossman and Lamb 2011). E23Q was
identified in both previous sets of experiments (Foll et al.
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Fig. 4.—Putatively beneficial mutations. The contending beneficial mutations (table 1) are tracked in the oseltamivir-only replicates (A–C), in the
combined drug replicates (D–F) and in the favipiravir-only and no drug populations (G and H). The key to these mutations is given below, with the NA
mutations in red. Clustering is observed amongst these beneficial mutations in combined drug replicates. All other segregating mutations (i.e., arising in only
one replicate) are assumed to be neutral or deleterious and are plotted in gray. In combined drug replicates, this class of mutations also shows evidence of
genetic hitchhiking with the resistance mutations, or with HA E78G (a ubiquitous contending beneficial mutation in all oseltamivir and combined drug
replicates, except for combined drug replicate 2) (D–F). In (G) and (H), the contending beneficial mutations are tracked in the favipiravir-only and no-drug
control populations, with longer trajectories (weaker selection coefficients) and less evidence of clustering.
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2014; Bank et al. 2016) and was significant in oseltamivir 1
(s¼ 0.057), favipiravir-only, and no-drug populations, with
trajectories typical of clonal interference in the other repli-
cates. A37G was very near to the previously identified A41V
and may serve a similar function in improving virion budding;
it clustered with D101N in some replicates and E23Q in others
and arose in oseltamivir 2 and 3 (s¼ 0.038) and combined 1
and 2. NP mutation D101N has been previously screened as a
resistance mutation to the mutagenic drug ribavirin (Cheung
et al. 2014) with inconclusive results; here, we found it to be
present in all populations except the no-drug control, includ-
ing the oseltamivir-only populations, and therefore may have
a role in improving the formation of infective virions (Noton
et al. 2009).
Although H275Y did not appear more rapidly in combined
drug populations than in oseltamivir-only replicates, the two
other NA nonsynonymous mutations described earlier
(A454V and E128G) only appeared in combined drug repli-
cates (fig. 4) and exhibit trajectories characteristic of strong
selection coefficients. We put forward the hypothesis that the
mutational effect of favipiravir allowed the virus to rapidly
explore sequence space for alternative resistance solutions
within the limits of the time to extinction imposed by the
increasing mutational load burden.
Effects of Genetic Hitchhiking
Under a model of genetic hitchhiking, neutral, or weakly se-
lected sites in physical linkage to strongly beneficial mutations
rise in frequency (Maynard Smith and Haigh 1974). Here, we
found that the positively selected nonsynonymous mutations
identified in the oseltamivir-only replicates showed strong
pairwise correlations in their allele trajectories in the combined
drug populations (supplementary table 4, Supplementary
Material online), which provides greater evidence of clustering
in the combined drug populations (fig. 4D–F) than in the
oseltamivir-only populations (fig. 4A–C). This clustering of
beneficial mutations may be seen around the strongly se-
lected NA mutations H275Y, A454V, and E128G (fig. 5 and
supplementary table 4, Supplementary Material online).
Potential beneficial mutations for cell adaptation including
D101N and A37G (with trajectories characterized by a low
selection coefficient in some replicates) are rapidly driven to
fixation by association with H275Y in combined replicate 1
and A454V in combined replicate 2. In contrast, genetic hitch-
hiking in the oseltamivir-only replicates is of synonymous (pre-
sumed neutral) variants (HA L73L with H275 in replicate 1 and
NA P326P with H275Y in replicate 2). This suggests that, in
addition to generating possible alternative oseltamivir resis-
tance mutations, the enhanced mutational input of favipiravir
may also serve to optimize combinations of beneficial muta-
tions on single haplotypes.
Tracking the remaining mutations specific to the combined
drug replicates and segregating in excess of 40% DAF, shows
that these also cluster with the strongly selected NA mutations
and with the ubiquitous HA mutation E78G (H275Y and
E78G in replicate 1, A454V in replicate 2, and A454V,
E128G, and HA E78G in replicate 3, see fig. 4D–F), with hi-
erarchical clustering analysis (fig. 5) and pairwise correlations
(supplementary table 4, Supplementary Material online) con-
firming this association. These mutations are unique to each
combined drug replicate and are therefore assumed to be
Table 1
Mutations Inferred to Be Evolving under Positive Selection
Seg Pos Ref Base Mut
Base
Type S/NS SNP WFABC sb Bayesian
P Value (P< 0)
Prev id Replicate Functional Interpretation
PA 199 G T S G58G 0.026 0.017 Y All Cell adaptation
PA 225 C T S D67D N osel3 Synonymous
HA 1,280 G A S L73L 0.099 0** N osel1 Synonymous
HA 1,294 A G NS E78G 0.114(1) 0** N osel123 and comb13 Possible epistasis with H275Y
0.117(3) 0**
HA 1,395 G A NS D112N 0.126 0** Y osel2 and no drug Cell adaptation
NP 346 G A NS D101N 0.027(1) 0.0349 Y all except no drug Cell adaptation
NA 403 A G NS E128G a N comb3 Possible resistance mutation
NA 843 C T NS H275Y 0.125(1) 0** Y osel123 and comb13 Known resistance mutation
0.209(2) 0**
0.218(3) 0**
NA 998 G T S P326P 0.075 0.002** N osel2 Synonymous
NA 1,381 C T NS A454V a N comb23 Possible resistance mutation
MP1 92 G C NS E23Q 0.057(1) 0** Y All Compensatory mutation
MP2 848 C G NS A37G 0.038(3) 0.039 N osel23 and comb12 Compensatory mutation
NS1 399 G A NS D125N 0.036 0.03 N osel2 and no drug Cell adaptation
aIn combined drug replicates only, strength not estimated (the assumptions of a constant mutation rate and of unlinked sites do not hold).
bThe numbers in brackets indicate the oseltamivir replicate used for the estimation (where the mutation arises in several replicates).
**signiﬁcant (P<0.005).
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Fig. 5.—Hierarchical cluster analysis on combined drug trajectories. Ward’s minimum variance criterion (Ward 1963) was used to cluster allele-
frequency trajectories. The dissimilarity distances are shown in panels (A) and the details of the clusters in subsequent panels (B–D) for replicates 1 and
2, and (B–G) for replicate 3. We observe hitchhiking patterns suggesting that either NA mutations (H275Y, A454V, or E128G) or HA E78G sweep other
beneficial and neutral/deleterious mutations to fixation. Other cluster groups containing contending beneficial mutations do not fix. On panel (A), synon-
ymous mutations are shown in gray font and nonsynonymous mutations in black. The pairwise correlations matrix in supplementary table 4, Supplementary
Material online, supports the hierarchical cluster analysis.
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largely the result of hitchhiking of neutral and deleterious
variants. The pairwise allele trajectory correlations are partic-
ularly high 1) in combined replicate 1 within cluster D (fig. 5)
that contains H275Y (0.965–0.997 pairwise correlations be-
tween NA H275Y and the mutations in cluster D, shown in
blue in supplementary table 4, Supplementary Material on-
line) and are reasonably high within cluster B that contains HA
E78G (0.708–0.849 pairwise correlations between HA E78G
and the mutations in cluster B, shown in green in supplemen-
tary table 4, Supplementary Material online); 2) in combined
replicate 2, within cluster B that contains NA A454V (0.814–
0.991 pairwise correlations between NA A454V and the other
mutations in cluster B, shown in green in supplementary table
4, Supplementary Material online); in combined replicate 3
within cluster F that contains HA E78G (0.980–0.994 pairwise
correlations between HA E78G and the mutations in cluster F,
in orange in supplementary table 4, Supplementary Material
online), within cluster G that contains NA A454V and NA
E128G (0.970–1.0 pairwise correlations between NA A454V
and the mutations in cluster G, shown in pink in supplemen-
tary table 4, Supplementary Material online), and within clus-
ter C (0.88 pairwise correlation between NA H275Y and the
other mutation in cluster C, shown in blue in supplementary
table 4, Supplementary Material online). These clusters of
mutations mostly fix by passage 10. Pairwise correlations out-
side of the clusters are lower than within the clusters and
support the hierarchical cluster analysis.
Thus, our analyses suggest that in the combined drug rep-
licates the strongly selected beneficial mutations hitchhike not
only other beneficial mutations but also a high mutation load
to fixation. The timing of the selective sweeps coincides with a
sharp decrease in the total number of segregating mutations
after passage 6 in combined replicate 1 and after passage 8 in
combined replicate 2 (fig. 2B), suggesting that the selective
sweeps reduce genome-wide variation but at the cost of fix-
ing deleterious mutations. A likely explanation is that the rapid
trajectory to fixation of the beneficial mutations does not al-
low sufficient time to purge the linked deleterious mutations,
particularly as effective population size has diminished and
selection is therefore less efficient. In addition, there is a rapid
and constant input of new deleterious mutations segregating
at a low frequency from the impact of favipiravir. Ultimately
this combined high load burden accelerates the decline in viral
fitness and precipitates the population towards extinction
(supplementary fig. 4, Supplementary Material online).
Thus, the strength of beneficial mutations (as indicated by
the shape of their trajectory and the corresponding WFABC
estimates) governed the size of the linked mutation load and
potentially accelerated the process of extinction. As shown,
the trajectories of mutations in the favipiravir-treated popula-
tion were more random and diffuse (fig. 4G), with fewer ob-
vious clusters. The tracked beneficial mutations in the
favipiravir-only population-mediated cell adaptation and
were less strongly selected than NA mutations in the
oseltamivir and combined drug replicates with longer trajec-
tories, giving purifying selection more time to act. The ab-
sence of strong selective sweeps reducing genome-wide
variation was reflected in the high and escalating number of
segregating mutations for favipiravir-only populations ob-
served in figure 2B. Notably, the favipiravir population
reached extinction by passage 15 (fig. 2A), compared with
passage 10 for combined replicate 1, suggesting a tentative
hypothesis that the weaker hitchhiking dynamics were at least
partly responsible for the later point of collapse.
Effects of Hill–Robertson Interference
In a nonrecombining, asexual population such as IAV, strongly
selected beneficial alleles arising on different haplotypes are in
competition for fixation (Fisher 1930; Muller 1932; Barton
2010). There is a build-up in negative linkage disequilibrium
between these “repulsion haplotypes” (Hill and Robertson
1966; McVean and Charlesworth 2000) (i.e., the beneficial
mutations and their linked variants are found associated less
frequently than by chance) and a reduction in the efficacy of
selection. It is important to note here that while IAV does not
recombine, it does reassort, thus these strong linkage effects
will persist within segments, but are not expected genome-
wide. In the combined drug replicates, we find examples of
nonstandard trajectories of beneficial mutations (known to be
mutations under weak positive selection in the oseltamivir-
only replicates), which were characterized by a rapid rise
and decline. These trajectories suggested patterns of clonal
interference between beneficial mutations: haplotypes carry-
ing the strongly selected NA mutations H275Y or A454V out-
compete haplotypes carrying weaker mutations mediating
cell adaptation, in cases where these weaker mutations did
not hitchhike with the resistance mutations. Indeed, in the
combined drug replicates, these weak beneficial mutations
only fixed if they were associated with the NA mutations.
For example, in combined replicate 1, the H275Y haplo-
type swept the associated NP D101N and A37G to fixation; its
rise coincided with the decline of haplotypes carrying E23Q. In
combined replicate 2, the rise of the haplotype carrying NA
A454V coincided with the extinction of MP1 E23Q, MP2
A37G, PA G58G, and NP D101N, until NP D101N was
reshuffled onto the A454V background and fixed. In com-
bined replicate 3, the rapid spread and fixation of haplotypes
carrying NA A454V, NA E128G, and HA E78G coincided with
the decline of MP1 E23Q. Some evidence of these effects is
present in the oseltamivir-only replicates but not in the
favipiravir-alone or no-drug replicates, where the spread of
beneficial mutations mediating cell adaptation followed more
standard trajectories characteristic of weakly selected muta-
tions (fig. 4D–F).
In the favipiravir population, we observed the influence of
a different form of interference between linked weakly se-
lected beneficial and deleterious mutations (weak-selection
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Hill–Robertson Interference) (Hill and Robertson 1966;
McVean and Charlesworth 2000). There was limited cluster-
ing and significant variance in allele trajectories over the lon-
ger lifespan of this population (fig. 4G). Linkage was likely
between weakly selected mutations mediating cell adaptation
and the increasing influx of slightly deleterious mutations. The
high variance in allele trajectories was not observed to the
same extent in the control (fig. 4H), the oseltamivir-only pop-
ulations (fig. 4A–C), or in the combined drug populations (fig.
4D–F). Hitchhiking of beneficial, deleterious, and neutral var-
iants with the resistance mutations accounts for almost all of
the trajectories in the mutations in the combined drug pop-
ulations, with the exception of combined replicate 1 passage
10 where genetic drift (i.e., Muller’s ratchet) led to the fixation
of many neutral and deleterious mutations owing to popula-
tion collapse.
Conclusion
To our knowledge, this represents the first genome-wide ex-
amination of the combined effects of oseltamivir and favipir-
avir treatment on virus populations. We found evidence of
mutational meltdown in combined drug populations leading
to extinction. Further, global estimates of effective population
size were consistent between the favipiravir-only and com-
bined drug replicates, and support an important role for
Muller’s ratchet in facilitating this extinction—where the loss
of the least loaded class is being driven both by genetic drift as
well as the elevated mutation rate. Intriguingly, despite a
lower mutation load, we observed a more rapid decline in
relative growth rate in the combined drug population relative
to the favipiravir-treated population. Strongly selected bene-
ficial mutations influence the evolutionary dynamics in com-
bined drug replicates by sweeping deleterious mutations to
fixation. The timing of these sweeps coincides with sharp
reductions in the number of segregating mutations after pas-
sage 6 in replicate 1 and passage 8 in replicate 2 (fig. 2B). This
striking evolutionary dynamic is not apparent in the favipiravir-
only population, where the identified beneficial mutations
only mediate cell adaptation (and no resistance mutations
are identified). Thus, fundamentally, these results suggest
an interesting evolutionary trade-off. On the one hand, the
combined drug effect may speed extinction owing to the
stronger association between oseltamivir resistance mutations
and the deleterious mutations induced by favipiravir treat-
ment. On the other hand, the sequence space underlying
oseltamivir resistance is explored rapidly under favipiravir
treatment, thus allowing for higher segregating frequencies
of a range of NA mutations in the population.
If indeed the hitchhiking of deleterious mutations is the
key factor accelerating extinction, it is noteworthy that
the strongly selected mutations required for hitchhiking
need not be oseltamivir resistance mutations per se—and
that in this experimental set-up those are simply the only
beneficial mutations of necessary effect size. This suggests
an interesting avenue of exploring combination treat-
ments that may similarly invoke these hitchhiking effects
to speed extinction under favipiravir treatment, but per-
haps combined with a partner for which beneficial muta-
tions would not be as clinically problematic as oseltamivir
resistance.
Supplementary Material
Supplementary data are available at Genome Biology and
Evolution online.
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